Matthew D. Hellmann
Lung cancer doctor who was the lead author of CheckMate 227, the trial that showed the immunotherapy pair nivolumab and ipilimumab helps people with advanced lung cancer live longer than chemotherapy alone.
Overview
Matthew Hellmann was first author of the CheckMate 227 reports in the New England Journal of Medicine, including the 2019 overall-survival analysis of nivolumab plus ipilimumab in previously untreated advanced non-small-cell lung cancer. His research at Memorial Sloan Kettering Cancer Center, where he practised as a thoracic oncologist, centred on tumour mutational burden and other predictors of response to immune checkpoint blockade.
Similar pages
not linked directly; found by shared links- PersonMartin Reck
Shares PD-L1-high non-small-cell lung cancer without a driver mutation, Non-small-cell lung cancer and the tags lung, immunotherapy, trialist.
- PersonAlice T. Shaw
Shares Lung cancer (all types), Non-small-cell lung cancer and the tags lung, trialist.
- PersonGregory J. Riely
Shares Lung cancer (all types), Non-small-cell lung cancer and the tags lung, trialist.
- PersonKeunchil Park
Shares Lung cancer (all types), Non-small-cell lung cancer and the tags lung, trialist.
- PersonPaul K. Paik
Shares Lung cancer (all types), Non-small-cell lung cancer and the tags lung, trialist.
- InstitutionLungenClinic Grosshansdorf
Shares Lung cancer (all types), PD-L1-high non-small-cell lung cancer without a driver mutation, Non-small-cell lung cancer.
- PersonRoy S. Herbst
Shares PD-L1-high non-small-cell lung cancer without a driver mutation, Non-small-cell lung cancer and the tags lung, immunotherapy.
- TrialKEYNOTE-407
Shares Lung cancer (all types), PD-L1-high non-small-cell lung cancer without a driver mutation, Non-small-cell lung cancer.